DDInter1625 DDInter609
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. It is used as monotherapy or in combination with other drugs, such as corticosteroids.[L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and chronic obstructive pulmonary disease. It is also being studied in combination with another antibody that which targets IL-33.
Dupilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Dupilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Dupilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Dupilumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Dupilumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Dupilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Fingolimod
Dupilumab may lead to a major life threatening interaction when taken with Upadacitinib